Ten-Year Follow-up Data From the AREDS2 Study

Related

• 

  Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen

  Michael J Allingham, MD, PhD

  Annual Meeting Talks

  2019

• 

  Effects of the Mitochondria-Targeted Drug Elamipretide on Leakage-Independent Vision Loss in Fellow Eyes with Neovascular AMD in the ReCLAIM Study

  Priyatham (Prithu) S Mettu, MD

  Updates from the Field

  2019

• 

  Therapeutic Horizons for Dry AMD

  Robert L. Avery, MD

  Updates from the Field

  2019